Cornea

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Ophthalmologists discuss topography-guided techniques, long-term corneal health, and emerging technologies set to transform refractive surgery.

Peter J. McDonnell, MD, reflects on his early experience managing bullous keratopathy with penetrating keratoplasty and how advances like DMEK have transformed outcomes across corneal, refractive, and cataract surgery.

Chiu discusses factors affecting adoption of the FDA-approved epi-on therapy, from clinic setup to insurance coverage, while highlighting its safety and efficacy.

Rajpal shares his perspectives on the newly FDA-approved treatment, clinical benefits, and its potential impact on keratoconus management.

The novel therapeutic for keratoconus does not require corneal epithelium removal and is slated to launch commercially in early 2026.

The trial evaluated the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.

The incision-free therapeutic for keratoconus is expected to be commercially available in early 2026, according to the company.

The epithelium-on cross-linking modality is designed to enable simultaneous, bilateral keratoconus treatment, according to Epion Therapeutics.

Additionally, the company plans to perform cash-saving actions, including a workforce reduction.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

Robotic laser arcuate incisions reduce variability and residual astigmatism.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.